 |  |  |  |  |  |
   | ||
|
Job Bank UCMC News Calendar Hospital Staff Administration Volunteers History Contact Us Qualifications and Awards Financial Arrangements Patient Rights and Responsibilities Advance Directives Visiting Hours Admissions and Discharge Gift Shop and Cafeteria
|  |
New Cervical Cancer Vaccine To Be Discussed
Prepared by: Steve Wong Upstate Carolina Medical Center Marketing Phone 864-487-1515 
Upstate Carolina Medical Center will host a free public seminar "HealthTalk" on Gardasil, the only vaccine that may help guard against cervical cancer. Gaffney-based obstetrician/gynecologist Dr. Steven Lewis will be the guest speaker. This free public event will be Tuesday, Feb. 20, in the cafeteria, 6-7 p.m. This information is especially important to young women, as young as 12-years-old. Minors should be accompanied by a parent. Space is limited, so please call in advance to register: 487-4271. This event is co-sponsored by the American Cancer Society. The American Cancer Society says females should be routinely vaccinated against human papilloma virus (HPV) at age eleven to 12 to prevent cervical cancer and its precursors. The new guidelines join those of other major health groups calling for vaccination among this group. The guidelines, published in the January/February 2007 issue of CA: A Cancer Journal for Clinicians, emphasize that the full potential of the vaccine will only be realized if vaccination can be achieved in groups of women for whom access to cervical screening is currently most problematic. "The vaccine holds remarkable potential, but unless the same populations of women who right now do not have access to or do not seek regular Pap tests get this vaccine, it will have limited impact," said Harmon J. Eyre, M.D., chief medical officer of the American Cancer Society and lead author of the guidelines. ?Also, as HPV vaccination for the prevention of cervical cancer is introduced and promoted, it remains critical that women undergo regular screening even if they have been vaccinated. The guidelines were created by an expert panel convened by the American Cancer Society to review existing data and develop recommendations for the public. The panel concluded: Routine HPV vaccination is recommended for females age 11 to 12 years. Females as young as 9 years may receive HPV vaccination. HPV vaccination is also recommended for females age 13 to 18 years to catch up missed vaccine or complete the vaccination series. There are currently insufficient data to recommend for or against universal vaccination of females age 19 to 26 years in the general population. A decision about whether a woman age 19 to 26 years should receive the vaccine should be based on an informed discussion between the woman and her health care provider regarding her risk of previous HPV exposure and potential benefit from vaccination. Ideally the vaccine should be administered prior to potential exposure to genital HPV through sexual intercourse because the potential benefit is likely to diminish with increasing number of lifetime sexual partners. HPV vaccination is not currently recommended for women over age 26 years or for males. Screening for cervical cancer and precancers should continue in both vaccinated and unvaccinated women according to current ACS early detection guidelines. In 2007, an estimated 11,1502 cases of invasive cervical cancer will be diagnosed in the U.S., and an estimated 3,670 women will die from this disease. Globally, cervical cancer is the second most common cause of cancer death in women, with an estimated 510,000 newly diagnosed cervical cancer cases and 288,000 deaths. In developing countries, cervical cancer is often the most common cancer in women. Virtually all cervical cancers are causally related to infections by HPV. Approximately 70 percent of cervical cancers are caused by HPV types 16 or 18. About 500,000 precancerous lesions (cervical intraepithelial neoplasia Grade 2 and 3; CIN2 and CIN3) are diagnosed each year in the United States, and about 50 to 60 percent are attributable to HPV16 and HPV18. Cervical cancer screening, including widespread implementation of the Pap test, has led to a 75 percent drop in incidence and a 74 percent drop in deaths from cervical cancer in the past 50 years. Still, the imperfect sensitivity of cytology testing is estimated to be responsible for 30 percent of all cervical cancers; provider errors in follow up of abnormal results accounts for another ten percent. Beyond the limitations of the test itself, the failure of some women at risk to receive regular screening tests also contributes to the burden of cervical cancer. Half of all women who develop cervical cancer in the U.S. have never been screened, and an additional ten percent will have not been screened within five years of their diagnosis. Significant racial and ethnic disparities exist with regard to incidence, mortality, and survival associated with the diagnosis of cervical cancer in this country. The FDA approved GARDASIL for the prevention of cervical cancer; cervical pre-cancers [cervical intraepithelial neoplasia (CIN) 2/3 and adenocarcinoma in situ (AIS)]; vulvar pre-cancers [vulvar intraepithelial neoplasia (VIN) 2/3]; and vaginal pre-cancers [vaginal intraepithelial neoplasia (VaIN) 2/3] caused by HPV types 16 and 18.? GARDASIL is also approved for the prevention of genital warts and low-grade cervical lesions (CIN 1) caused by HPV types 6, 11, 16 and 18.? GARDASIL is approved for 9- to 26-year-old girls and women. "Merck is proud to be the leader in cervical cancer vaccine research and development," said Richard T. Clark, chief executive officer and president, Merck & Co., Inc. "Bringing forward this life-saving scientific advance is yet another testament to Merck's long-standing mission to research and develop novel vaccines and medicines that can greatly improve public health."
|
